Drugs for Chorea, Childhood-Onset, with Psychomotor Retardation (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):
(show top 50)
(show all 77)
# |
|
Name |
Status |
Phase |
Clinical Trials |
Cas Number |
PubChem Id |
1 |
|
Dopamine |
Approved |
Phase 4 |
|
51-61-6, 62-31-7 |
681 |
Synonyms:
(3H)-Dopamine
.alpha.-(3,4-Dihydroxyphenyl)-.beta.-aminoethane
.Beta.-(3,4-Dihydroxyphenyl)ethylamine hydrochloride
1,2-Benzenediol, 4-(2-aminoethyl)- (9CI)
1,2-Benzenediol, 4-(2-aminoethyl)-, hydrochloride
1,2-Benzenediol, 4-(2-aminoethyl)-, labeled with tritium
153C5321-5FEE-4B0B-8925-F388F0EEEBD1
2-(3,4-dihydroxyphenyl)ethylamine
2-(3,4-Dihydroxyphenyl)ethylamine
2-benzenediol
3,4 Dihydroxyphenethylamine
3,4-dihydroxyphenethylamine
3,4-Dihydroxyphenethylamine
3,4-Dihydroxyphenethylamine hydrochloride
3,4-Dihydroxyphenylethylamine
3-Hydroxtyramine
3-Hydroxytyramine
3-Hydroxytyramine Hydrobromide
3-Hydroxytyramine hydrochloride
4-(2-Aminoethyl)-1,
4-(2-aminoethyl)-1,2-benzenediol
4-(2-Aminoethyl)-1,2-benzenediol
4-(2-Aminoethyl)-1,2-bezenediol
4-(2-Aminoethyl)benzene-1,2-diol
4-(2-aminoethyl)catechol
4-(2-Aminoethyl)catechol
4-(2-aminoethyl)pyrocatechol
4-(2-aminoethyl)-pyrocatechol
4-(2-Aminoethyl)pyrocatechol
4-(2-Aminoethyl)-pyrocatechol
4-(2-Aminoethyl)pyrocatechol hydrochloride
50444-17-2
51-61-6
62-31-7 (HYDROCHLORIDE)
a-(3,4-Dihydroxyphenyl)-b-aminoethane
AC1L19S5
AC1Q54AX
AC1Q54AY
AKOS003790978
alpha-(3,4-Dihydroxyphenyl)-beta-aminoethane
ASL 279
BIDD:ER0506
Biomol-NT_000001
BPBio1_001123
BSPBio_001932
C03758
CHEBI:18243
CHEMBL59
CID681
cMAP_000036
cMAP_000065
D07870
DB00988
Deoxyepinephrine
DivK1c_000780
Dopamin
Dopamina
Dopamina [INN-Spanish]
dopamine
Dopamine
Dopamine (INN)
Dopamine (USAN)(*hydrochloride*)
Dopamine [INN:BAN]
Dopamine hydrochloride
Dopaminum
Dopaminum [INN-Latin]
Dopastat
Dophamine
Dynatra
EINECS 200-110-0
HSDB 3068
Hydrochloride, dopamine
|
Hydroxytyramin
hydroxytyramine
Hydroxytyramine
IDI1_000780
intropin
Intropin
Intropin [*hydrochloride*]
IP 498
KBio1_000780
KBio2_001492
KBio2_002388
KBio2_002484
KBio2_004060
KBio2_004956
KBio2_005052
KBio2_006628
KBio2_007524
KBio2_007620
KBio3_001152
KBio3_002867
KBio3_002962
KBioGR_001129
KBioGR_002388
KBioGR_002484
KBioSS_001492
KBioSS_002393
KBioSS_002491
KW-3-060
L000232
L-DOPAMINE
LDP
Lopac0_000586
Lopac-H-8502
LS-159
Medopa (TN)
m-Hydroxytyramine hydrochloride
MolPort-001-641-000
NCGC00015519-01
NCGC00015519-08
NCGC00096050-01
NCGC00096050-02
NCGC00096050-03
NCGC00096050-04
NCGC00096050-05
nchembio.105-comp9
nchembio.107-comp4
nchembio.284-comp1
nchembio.78-comp16
nchembio.89-comp3
nchembio705-8
nchembio801-comp8
NINDS_000780
NSC 173182
NSC169105
NSC173182
Oprea1_088821
Oxytyramine
Pyrocatechol, 4-(2-aminoethyl)- (8CI)
Pyrocatechol, 4-(2-aminoethyl)-, hydrochloride
Revimine
Revivan
SPBio_001205
Spectrum_001012
SPECTRUM1505155
Spectrum2_001023
Spectrum3_000406
Spectrum4_000525
Spectrum5_000945
ST048774
STK301601
UNII-VTD58H1Z2X
UPCMLD0ENAT5885989:001
|
|
2 |
|
Amantadine |
Approved |
Phase 4 |
|
768-94-5 |
2130 |
Synonyms:
1 Aminoadamantane
138576_ALDRICH
1-Adamantamine
1-adamantanamine
1-Adamantanamine
1-Adamantanamine (8CI)
1-adamantylamine
1-Adamantylamine
1-aminoadamantane
1-Aminoadamantane
1-Aminotricyclo(3.3.1.1(sup 3,7))decane
665-66-7 (hydrochloride)
768-94-5
AB00514655
AbZ brand OF amantadine hydrochloride
AC-11992
AC1L1CZI
AC1Q4UAF
AC1Q5396
Adamantamine
adamantan-1-amine
adamantan-1-ylamine
Adamantanamine
ADAMANTANE,1-AMINO
Adamantylamine
Adekin
AKOS000113994
AKOS000119324
AL, amantadin
Aliud brand OF amantadine sulfate
Alliance brand OF amantadine hydrochloride
Aman
Amant
Amanta
Amanta hci azu
Amanta sulfate azu
Amantadin al
Amantadin azu
Amantadin neuraxpharm
Amantadin ratiopharm
Amantadin stada
Amantadina
Amantadina [INN-Spanish]
Amantadina juventus
Amantadina llorente
amantadine
Amantadine
Amantadine (INN)
Amantadine [INN:BAN]
Amantadine base
Amantadine Base
Amantadine HCL
amantadine hydrochloride
Amantadine hydrochloride
Amantadine sulfate
Amantadinneuraxpharm
Amantadin-neuraxpharm
Amantadinratiopharm
Amantadin-ratiopharm
Amantadinum
Amantadinum [INN-Latin]
Amanta-hci-azu
AmantaHCIAZU
Amantasulfateazu
Amanta-sulfate-azu
Amantidine
Ambap768-94-5
Aminoadamantane
Amixx
AZU, amantadin
Azupharma brand OF amantadine hydrochloride
Azupharma brand OF amantadine sulfate
BIA4304
BIDD:GT0757
Bio-0821
BPBio1_000368
BRN 2204333
BSPBio_000334
BSPBio_001570
BSPBio_001822
C06818
C10H17N
Cerebramed
CHEBI:2618
CHEMBL660
Ciba geigy brand OF amantadine hydrochloride
Ciba-geigy brand OF amantadine hydrochloride
CID2130
D07441
DB00915
Desitin brand OF amantadine hydrochloride
DivK1c_000815
Du pont brand OF amantadine hydrochloride
EINECS 212-201-2
Endantadine
endo Brand OF amantadine hydrochloride
Gen amantadine
Gen-amantadine
GenAmantadine
Gen-Amantadine
Genpharm brand OF amantadine hydrochloride
Hexal brand OF amantadine sulfate
|
HMS1791O12
HMS1989O12
Hormosan brand OF amantadine sulfate
HSDB 3202
Hydrochloride, amantadine
I14-1101
IDI1_000815
InChI=1/C10H17N/c11-10-4-7-1-8(5-10)3-9(2-7)6-10/h7-9H,1-6,11H
infecto Flu
infecto-Flu
InfectoFlu
Infectopharm brand OF amantadine hydrochloride
Infex
Juventus brand OF amantadine hydrochloride
Juventus, amantadina
KBio1_000815
KBio2_000390
KBio2_002958
KBio2_005526
KBio3_001322
KBioGR_000548
KBioSS_000390
Krewel brand OF amantadine hydrochloride
L000868
Llorente brand OF amantadine hydrochloride
Llorente, amantadina
Lopac0_000004
Lopac-A-1260
LS-157049
Mantadine
Mantadix
Merz brand OF amantadine sulfate
Midantan
MolPort-001-661-700
MolPort-001-760-587
MolPort-001-791-102
NCGC00015036-01
NCGC00015036-07
NCGC00162039-01
NCGC00162039-02
NCGC00162039-03
NCGC00162039-04
NCGC00179597-01
NCIOpen2_001059
Neuraxpharm brand OF amantadine sulfate
neuro Hexal brand OF amantadine sulfate
NINDS_000815
Novartis brand OF amantadine hydrochloride
NSC 341865
NSC341865
NSC83653
Oprea1_248648
OR14310
Orion brand OF amantadine hydrochloride
Pharmascience brand OF amantadine hydrochloride
Pk-merz
Pk-Merz
PMS Amantadine
PMSAmantadine
PMS-Amantadine
Prestwick0_000407
Prestwick1_000407
Prestwick2_000407
Prestwick3_000407
Ratiopharm brand OF amantadine hydrochloride
Solvay brand OF amantadine hydrochloride
SPBio_000002
SPBio_002273
Spectrum_000030
Spectrum2_000081
Spectrum3_000291
Spectrum4_000134
Spectrum5_000772
Stada brand OF amantadine hydrochloride
Stada brand OF amantadine sulfate
Stada, amantadin
STK298781
Sulfate, amantadine
Symadine
Symmetrel
TCMDC-125869
Thiemann brand OF amantadine hydrochloride
TL8005280
Tregor
Tricyclo(3.3.1.1(3,7))-decan-1-amine
Tricyclo(3.3.1.1(sup 3,7))decan-1-amine
Tricyclo(3.3.1.1(sup 3.7))decan-1-amine
Tricyclo(3.3.1.13,7)decan-1-amine
tricyclo[3.3.1.1(3,7)]Decan-1-amine
Tricyclo[3.3.1.1(3,7)]decan-1-amine
tricyclo[3.3.1.1(3,7)]decan-1-ylamine
tricyclo[3.3.1.1(3,7)]Decan-1-ylamine
tricyclo[3.3.1.1(3,7)]decane-1-amine
tricyclo[3.3.1.1(3,7)]Decane-1-amine
Tricyclo[3.3.1.1(sup3,7)]decan-1-amine
Tricyclo[3.3.1.1^3,7]decan-1-amine
tricyclo[3.3.1.1~3,7~]decan-1-amine
UNII-BF4C9Z1J53
Viregyt
Virosol
Wiregyt
WLN: L66 B6 A B- C 1B ITJ BZ
|
|
3 |
|
Levodopa |
Approved |
Phase 4 |
|
59-92-7 |
6047 |
Synonyms:
(-)-(3,4-Dihydroxyphenyl)alanine
(−)-3-(3,4-dihydroxyphenyl)-L-alanine
(-)-3-(3,4-Dihydroxyphenyl)-L-alanine
(−)-dopa
(-)-Dopa
(2S)-2-amino-3-(3,4-Dihydroxyphenyl)propanoate
(2S)-2-amino-3-(3,4-dihydroxyphenyl)propanoic acid
(2S)-2-amino-3-(3,4-Dihydroxyphenyl)propanoic acid
.Beta.-(3, 4-Dihydroxyphenyl)alanine
.Beta.-(3,4-Dihydroxyphenyl)-L-alanine
1E83F927-C221-46AA-B90A-81B33C5F3868
23734-74-9
25525-15-9
2-Amino-3-(3,4-dihydroxyphenyl)propanoic acid
3 Hydroxy L tyrosine
3-(3,4-Dihydroxypheny
3-(3,4-Dihydroxyphenyl)-L-alanine
3, 4-Dihydroxy-L-phenylalanine
3, 4-Dihydroxyphenylalanine
3,4-dihydroxy-L-phenylalanine
3,4-Dihydroxy-L-phenylalanine
3,4-dihydroxyphenylalanine
3,4-Dihydroxyphenylalanine
3,4-DIHYDROXYPHENYLALANINE
3,4-Dihydroxyphenylalanine (VAN)
3,4-Dihydroxyphenyl-L-alanine
34241-25-3
37830_FLUKA
3-Hydroxy-L-tyrosine
587-45-1
59-92-7
72572-99-7
72573-00-3
88250-23-1
90638-38-3
AC-11686
AC1L1LOR
AC1Q4U7F
b-(3,4-Dihydroxyphenyl)-a-L-alanine
b-(3,4-Dihydroxyphenyl)alanine
b-(3,4-Dihydroxyphenyl)-L-alanine
Bendopa
beta-(3,4-Dihydroxyphenyl)alanine
beta-(3,4-Dihydroxyphenyl)-alpha-alanine
beta-(3,4-Dihydroxyphenyl)-alpha-L-alanine
beta-(3,4-Dihydroxyphenyl)-L-alanine
BIDD:GT0158
Bio-0575
Biodopa
bmse000322
BPBio1_000059
Brocadopa
BSPBio_000053
BSPBio_002354
C00355
C9H11NO4
CAS-59-92-7
CCRIS 3766
Cerepap
CHEBI:15765
CHEMBL1009
CID6047
Cidandopa
component of Sinemet
D 9628
D00059
D0600
D9628
D9628_SIGMA
DAH
DB01235
Deadopa
Dihydroxy-L-phenylalanine
Dihydroxyphenylalanine
DivK1c_000452
Dopa
DOPA
Dopaflex
Dopaidan
Dopal
Dopal-fher
Dopal-Fher
Dopalina
Dopar
Dopar (TN)
Doparkine
Doparl
Dopasol
Dopaston
Dopaston SE
Dopastone
Dopastral
Dopicar
Doprin
EINECS 200-445-2
Eldopal
Eldopar
Eldopatec
EU-0100454
Eurodopa
Helfo DOPA
|
helfo-Dopa
Helfo-Dopa
HMS1568C15
HMS1922J14
HMS2090O08
HMS2093N04
HMS501G14
HSDB 3348
IDI1_000452
InChI=1/C9H11NO4/c10-6(9(13)14)3-5-1-2-7(11)8(12)4-5/h1-2,4,6,11-12H,3,10H2,(H,13,14
Insulamina
IV Levodopa
KBio1_000452
KBio2_000934
KBio2_003502
KBio2_006070
KBioGR_001177
KBioSS_000934
L 3,4 Dihydroxyphenylalanine
L Dopa
L(-)-Dopa
L-(-)-Dopa
L-(3, 4-Dihydroxyphenyl)-.alpha.-alani
L-(3, 4-Dihydroxyphenyl)alanine
L-(o-Dihydroxyphenyl)alanine
l)-L-alanine
L-.Beta.-(3,4-Dihydroxyphenyl)alanine
L-3-(3,4-Dihydroxyphenyl)alanine
L-3-(3,4-Dihydroxyphenyl)-alanine
L-3,4-dihydroxyphenylalanine
L-3,4-Dihydroxyphenylalanine
L-3-Hydroxytyrosine
L-4-5-Dihydroxyphenylalanine
Laradopa
Larodopa
L-b-(3,4-Dihydroxyphenyl)-a-alanine
L-b-(3,4-Dihydroxyphenyl)alanine
L-beta-(3,4-Dihydroxyphenyl)alanine
L-beta-(3,4-Dihydroxyphenyl)-alpha-alanine
L-Dihydroxyphenylalanine
L-DOPA
L-DOPA, Parcopa, Atamet, Stalevo, Madopar, Prolopa, Dopar, 3,4-Dihydroxyphenylalanine, Levodopa
Ledopa
Levedopa
Levodopa
Levodopa (JP15/USP)
Levodopa (JP15/USP/INN)
Levodopa [USAN:INN:BAN:JAN]
Levodopum
Levodopum [INN-Latin]
Levopa
L-O-Dihydroxyphenylalanine
L-o-Hydroxytyrosine
Lopac0_000454
Lopac-D-9628
LS-255
L-β-(3,4-dihydroxyphenyl)alanine
Maipedopa
medphano Brand OF levodopa
MLS000028514
MolPort-000-856-937
NCGC00015384-01
NCGC00016270-01
NCGC00016270-06
NCGC00093869-04
nchembio.2007.55-comp26
nchembio.89-comp9
ne
NINDS_000452
NSC 118381
NSC118381
Parda
Pardopa
PDSP1_001541
PDSP2_001525
Prestwick_185
Prestwick0_000017
Prestwick1_000017
Prestwick2_000017
Prestwick3_000017
Prodopa
Ro 4-6316
Roberts brand OF levodopa
Roche brand OF levodopa
S1726_Selleck
SDCCGMLS-0066924.P001
SMR000058312
Sobiodopa
SPBio_000391
SPBio_001974
Spectrum_000454
Spectrum2_000496
SPECTRUM2300205
Spectrum4_000539
Spectrum5_001899
Syndopa
UNII-46627O600J
Veldopa
Weldopa
β-(3,4-dihydroxyphenyl)alanine
β-(3,4-dihydroxyphenyl)-L-alanine
|
|
4 |
|
Carbidopa |
Approved |
Phase 4 |
|
28860-95-9 |
34359 |
Synonyms:
(-)-L-a-hydrazino-3,4-Dihydroxy-a-methylhydrocinnamate
(-)-L-a-hydrazino-3,4-Dihydroxy-a-methylhydrocinnamic acid
(-)-L-alpha-hydrazino-3,4-Dihydroxy-alpha-methylhydrocinnamate
(-)-L-alpha-hydrazino-3,4-Dihydroxy-alpha-methylhydrocinnamic acid
(-)-L-alpha-Hydrazino-3,4-dihydroxy-alpha-methylhydrocinnamic acid
(-)-L-alpha-Hydrazino-3,4-dihydroxy-alpha-methylhydrocinnamic acid monohydrate
(-)-L-α-hydrazino-3,4-dihydroxy-α-methylhydrocinnamate
(-)-L-α-hydrazino-3,4-dihydroxy-α-methylhydrocinnamic acid
(2S)-3-(3,4-dihydroxyphenyl)-2-hydrazino-2-methylpropanoic acid
(2S)-3-(3,4-dihydroxyphenyl)-2-hydrazinyl-2-methylpropanoic acid
(2S)-3-(3,4-dihydroxyphenyl)-2-hydrazinyl-2-methylpropanoic acid hydrate
(2S)-3-(3,4-dihydroxyphenyl)-2-hydrazinyl-2-methylpropanoic acid monohydrate
(2S)-3-(3,4-dihydroxyphenyl)-2-hydrazinyl-2-methylpropanoic acid--water (1/1)
(AlphaS)-a-hydrazino-3,4-dihydroxy-a-methylbenzenepropanoate
(AlphaS)-a-hydrazino-3,4-dihydroxy-a-methylbenzenepropanoic acid
(AlphaS)-alpha-hydrazino-3,4-dihydroxy-alpha-methylbenzenepropanoate
(alphaS)-alpha-hydrazino-3,4-dihydroxy-alpha-methylbenzenepropanoic acid
(AlphaS)-alpha-hydrazino-3,4-dihydroxy-alpha-methylbenzenepropanoic acid
(alphaS)-alpha-hydrazino-3,4-dihydroxy-alpha-methylbenzenepropanoic acid monohydrate
(AlphaS)-α-hydrazino-3,4-dihydroxy-α-methylbenzenepropanoate
(AlphaS)-α-hydrazino-3,4-dihydroxy-α-methylbenzenepropanoic acid
(S)-(-)-carbidopa
(S)-(−)-carbidopa
(S)-(-)-Carbidopa
(S)-(-)-carbidopa hydrate
(S)-alpha--Hydrazino-3,4-dihydroxy-alpha--methyl-benzenepropanoic acid monohydrate
(S)-carbidopa
(S)-Carbidopa
(S)-carbidopa hydrate
(αS)-α-hydrazino-3,4-dihydroxy-α-methylbenzenepropanoic acid
27925-91-3
28860-95-9
31823-41-3
38821-49-7
AC-1676
AC1L1RFR
AC1L1Z32
AC1Q5QGW
alpha-Hydrazino-alpha-methyl-beta-(3,4-dihydroxyphenyl)propionic acid
alpha-Methyldopahydrazine
Atamet
BB_SC-5095
Benzenepropanoic acid, alpha-hydrazino-3,4-dihydroxy-alpha-methyl-, monohydrate, (S)
C-126
C126_SIGMA
C1335_SIGMA
carbidopa
Carbidopa
Carbidopa (anhydrous)
Carbidopa [USAN:INN:BAN]
Carbidopa anhydrous
Carbidopa hydrate
Carbidopa Monohydrate
Carbidopa, (R)-isomer
Carbidopa, (S)-isomer
Carbidopa, (S)-Isomer
Carbidopa, Entacapone, & Levodopa
Carbidopa-1-wasser
|
Carbidopum
Carbidopum [INN-Latin]
carbidopum monohydricum
CCRIS 5093
C-DOPA
CHEBI:3395
CHEBI:39585
CHEMBL1200748
CHEMBL1201236
CID34359
CID38101
CPD-11550
DB00190
EINECS 249-271-9
EU-0100382
Hadrazino-alpha-methyldopa
HMS2089B12
Hydrocinnamic acid, (-)-L-alpha-hydrazino-3,4-dihydroxy-alpha-methyl-, monohydrate
KINSON, 3-(3,4-DIHYDROXY-PHENYL)-2-HYDRAZINO-2-METHYL-PROPIONIC ACID
L-3-(3,4-Dihydroxyphenyl)-2-methyl-2-hydrazinopropionate
L-3-(3,4-dihydroxyphenyl)-2-methyl-2-hydrazinopropionic acid
L-3-(3,4-Dihydroxyphenyl)-2-methyl-2-hydrazinopropionic acid
L-alpha-(3,4-dihydroxybenzyl)-alpha-hydrazinopropionic acid monohydrate
L-alpha-Methyl-alpha-hydrazino-beta-(3,4-dihydroxyphenylpropionic acid
L-alpha-Methyl-beta-(3,4-dihydroxyphenyl)-alpha-hydrazinopropionic acid
L-alpha-Methyldopahydrazine
L-a-Methyldopahydrazine
Lodosin
Lodosyn
Lodosyn, Carbidopa
Lopac0_000382
LS-77199
L-α-methyldopahydrazine
Methyldopahydrazine
MK 486
MK-485
MK-486
MLS000069628
MLS002207014
MolPort-003-940-629
MolPort-005-934-181
N-Aminomethyldopa
NCGC00024596-01
NCGC00024596-03
NCGC00024596-05
NCGC00024596-06
S-(-)-alpha-Hydrazino-3,4-dihydroxy-2-methylbenzenepropanoic acid
S(-)-alpha-Hydrazino-3,4-dihydroxy-alpha-methylhydrocinnamic acid monohydrate
S-(-)-Carbidopa
S(-)-CARBIDOPA
S1891_Selleck
SMP1_000057
SMR000058235
ST055523
Stalevo
Tocris-0455
UNII-KR87B45RGH
UNII-MNX7R8C5VO
|
|
5 |
|
Selegiline |
Approved, Investigational, Vet_approved |
Phase 4 |
|
14611-51-9 |
5195 26757 |
Synonyms:
(-)-(N)-Methyl-N-((1R)-1-methyl-2-phenylethyl)prop-2-yn-1-amine
(-)-Deprenil
(−)-selegiline
(2R)-N-methyl-1-phenyl-N-prop-2-ynylpropan-2-amine
(R)-(-)-N,alpha-Dimethyl-N-2-propinylphenethylamine
(R)-(-)-N-Methyl-N-(1-phenyl-2-propyl)-2-propinylamin
14611-51-9
14611-52-0 (hydrochloride)
2079-54-1 (deprenyl.hydrochloride)
AC1L1BTZ
AC1Q2860
AKOS000281115
Anipryl
Apo-Selegiline
BPBio1_000687
BRD-K86434416-001-02-7
BRD-K86434416-003-03-1
Bristol myers squibb brand OF selegiline
Bristol-myers squibb brand OF selegiline
BSPBio_000623
BSPBio_001589
C07245
C13H17N
Carbex
CHEBI:9086
CHEMBL972
CID26757
D03731
DB01037
Deprenalin
Deprenil
Deprenyl
Eldepryl
Emsam
Emsam (TN)
Gen-Selegiline
HMS1791P11
HMS1989P11
HMS2089D09
Humex
Hydrochloride, selegiline
Jumex
L-Deprenalin
L-Deprenyl
|
l-E 250
LS-30156
MolPort-000-883-771
NCGC00024994-01
NCGC00024994-02
NCGC00024994-03
NCGC00024994-04
N-methyl-N-[(1R)-1-methyl-2-phenylethyl]prop-2-yn-1-amine
N-methyl-N-[(2R)-1-phenylpropan-2-yl]prop-2-yn-1-amine
Novo-Selegiline
Nu-Selegiline
Prestwick0_000552
Prestwick1_000552
Prestwick2_000552
Prestwick3_000552
Sd Deprenyl
Selegeline Hcl
Selegilina
Selegilina [INN-Spanish]
selegiline
Selegiline
Selegiline (USAN/INN)
Selegiline [INN:BAN]
Selegiline hydrochloride
Selegiline hydrochloride, (R)-isomer
Selegiline hydrochloride, (R,S)-isomer
Selegiline hydrochloride, (S)-isomer
Selegiline Transdermal System (STS) patch
Selegiline valeant brand
Selegiline, (R)-isomer
Selegiline, (R)-Isomer
Selegiline, (R,S)-isomer
Selegiline, (S)-isomer
Selegilinum
Selegilinum [INN-Latin]
Selegyline
SPBio_002544
STK640578
Tocris-1095
UNII-2K1V7GP655
Valeant brand OF selegiline
Yumex
Zelapar
ZINC19632633
|
|
6 |
|
Carbidopa, levodopa drug combination |
|
Phase 4 |
|
|
|
7 |
|
Dihydroxyphenylalanine |
|
Phase 4 |
|
|
|
8 |
|
Psychotropic Drugs |
|
Phase 4 |
|
|
|
9 |
|
Dopamine Agents |
|
Phase 4 |
|
|
|
10 |
|
Antiparkinson Agents |
|
Phase 4 |
|
|
|
11 |
|
Anti-Infective Agents |
|
Phase 4 |
|
|
|
12 |
|
Analgesics, Non-Narcotic |
|
Phase 4 |
|
|
|
13 |
|
Antiviral Agents |
|
Phase 4 |
|
|
|
14 |
|
Analgesics |
|
Phase 4 |
|
|
|
15 |
|
Dopamine agonists |
|
Phase 4 |
|
|
|
16 |
|
Aromatic Amino Acid Decarboxylase Inhibitors |
|
Phase 4 |
|
|
|
17 |
|
Antidepressive Agents |
|
Phase 4 |
|
|
|
18 |
|
Neuroprotective Agents |
|
Phase 4 |
|
|
|
19 |
|
Monoamine Oxidase Inhibitors |
|
Phase 4 |
|
|
|
20 |
|
Protective Agents |
|
Phase 4 |
|
|
|
21 |
|
Tetrabenazine |
Approved, Investigational |
Phase 3 |
|
58-46-8 |
6018 |
Synonyms:
1,2,4,6,7,11b-hexahydro-3-isobutyl-9,10-dimethoxy-2H-benzo[a]quinolizin-2-one
1,2,4,6,7,11b-hexahydro-3-Isobutyl-9,10-dimethoxy-2H-benzo[a]quinolizin-2-one
1,3,4,6,7,11b-Hexahydro-3-isobutyl-9,10-dimethoxy-2H-benzo(a)quinolizin-2-one
1,3,4,6,7,11b-Hexahydro-3-isobutyl-9,10-dimethoxy-2H-benzo[a]quinolizin-2-one
1,3,4,6,7,11b-hexahydro-9,10-dimethoxy-3-(2-methylpropyl)-2H-Benzo[a]quinolizin-2-one
2H-Benzo(a)quinolizin-2-one, 1,3,4,6,7,11b-hexahydro-9,10-dimethoxy-3-(2-methylpropyl)- (9CI)
2-oxo-3-isobutyl-9,10-dimethoxy-1,2,3,4,6,7-hexahydro-11bH-benzo[a]quinolizine
2-oxo-3-Isobutyl-9,10-dimethoxy-1,2,3,4,6,7-hexahydro-11BH-benzo[a]quinolizine
2-Oxo-3-isobutyl-9,10-dimethoxy-1,2,3,4,6,7-hexahydro-11bH-benzo[a]quinolizine
2-Oxo-3-isobutyl-9,10-dimethoxy-1,3,4,6,7,11.beta.-hexahydro-2H-benzoquinolizine
2-Oxo-3-isobutyl-9,10-dimethoxy-1,3,4,6,7,11-beta-hexahydro-2H-benzoquinolizine
2-oxo-3-isobutyl-9,10-dimethoxy-1,3,4,6,7,11b-hexahydro-2H-benzoquinolizine
2-oxo-3-Isobutyl-9,10-dimethoxy-1,3,4,6,7,11b-hexahydro-2H-benzoquinolizine
5-21-13-00178 (Beilstein Handbook Reference)
58-46-8
9,10-dimethoxy-3-(2-methylpropyl)-1,3,4,6,7,11b-hexahydro-2H-pyrido[2,1-a]isoquinolin-2-one
9,10-dimethoxy-3-(2-methylpropyl)-1,3,4,6,7,11b-hexahydrobenzo[a]quinolizin-2-one
A2708/0115225
AC1L1LMF
AI3-52046
AKOS001681311
BRD-A47564106-001-01-8
BRN 0040090
C11168
Cambridge laboratories brand OF tetrabenazine
CHEBI:293281
CHEMBL117785
CID6018
D08575
DB04844
EINECS 200-383-6
HMS1540E17
LS-40294
MLS001249426
MLS001249497
MLS003106727
MolPort-002-712-672
NCGC00160421-01
NCGC00160421-02
Nitoman
|
Nitoman (TN)
Nitoman, Xenazine, Tetrabenazine
NSC 169886
NSC169886
NSC172187
Oprea1_264344
Orphan brand OF tetrabenazine
Regulin
ro 1-9569
Ro 1-9569
Ro 1-9569/12
Roche brand OF tetrabenazine
Rubigen
S1789_Selleck
Shire brand OF tetrabenazine
SMR000718664
ST028814
STK678061
TBZ
tetra Benazin
Tetra benazin
Tetrabenazina
Tetrabenazina [inn-spanish]
Tetrabenazina [INN-Spanish]
Tetrabenazine
TETRABENAZINE
Tetrabenazine (INN)
Tetrabenazine [INN:BAN]
Tetrabenazine orphan brand
Tetrabenazinum
Tetrabenazinum [inn-latin]
Tetrabenazinum [INN-Latin]
Tetrabenzaine
Tetrabenzine
TimTec1_002217
TL8005032
UNII-Z9O08YRN8O
WLN: T B666 DV GNTT&J E1Y1&1 LO1 MO1
Xenazine
Xenazine (TN)
|
|
22 |
|
Paroxetine |
Approved, Investigational |
Phase 3 |
|
61869-08-7 |
43815 |
Synonyms:
(−)-(3S,4R)-4-(p-fluorophenyl)-3-((3,4-(methylenedioxy)phenoxy)methyl)piperidine
(-)-(3S,4R)-4-(p-Fluorophenyl)-3-((3,4-(methylenedioxy)phenoxy)methyl)piperidine
(-)-(3S,4R)-4-(P-Fluorophenyl)-3-((3,4-(methylenedioxy)phenoxy)methyl)piperidine
(-)-(3S,4R)-4-(p-Fluorophenyl)-3-((3,4-methylenedioxy)phenoxy)methyl)piperidine
(-)-Paroxetine
(-)-trans-4-(4-Fluorophenyl)-3-(3,4-methylenedioxyphenoxymethyl)piperidine
(-)-trans-4-(p-fluorophenyl)-3-[[3,4-(methylenedioxy)phenoxy]methyl]-piperidine
(3S,4R)-3-(1,3-benzodioxol-5-yloxymethyl)-4-(4-fluorophenyl)piperidine
(3S,4R)-3-[(1,3-benzodioxol-5-yloxy)methyl]-4-(4-fluorophenyl)piperidine
(3S-trans)-3-((1,3-benzodioxol-5-yloxy)methyl)-4-(4-fluorophenyl)piperidine
(3S-trans)-3-((1,3-Benzodioxol-5-yloxy)methyl)-4-(4-fluorophenyl)piperidine
(3S-trans)-3-[(1,3-Benzodioxol-5-yl-oxy)methyl]-4-(4-fluorophenyl)piperidine
[3H]Paroxetine
110429-35-1
3-(Benzo[1,3]Dioxol-5-Yl-Oxymethyl)-4-(4-Fluoro-Phenyl)-Piperidine Hydrochloride
61869-08-7
63952-24-9
64006-44-6 (maleate)
78246-49-8 (hydrochloride)
AB00514724
AC1L2AKL
AC1Q1H18
AC1Q4LV6
Acetate, paroxetine
Anhydrous, paroxetine hydrochloride
Aropax
BIDD:GT0673
BPBio1_000949
BRD-K37991163-003-02-7
BRL 29060
BRL-29060
BSPBio_000861
C07415
C19H20FNO3
Casbol
CHEBI:7936
CHEMBL490
CID43815
D02362
DB00715
DivK1c_006884
FG 7051
FG-7051
Frosinor
FT-0085087
Hemihydrate paroxetine hydrochloride
Hemihydrate, paroxetine hydrochloride
HMS2090H05
Hydrochloride anhydrous, paroxetine
Hydrochloride hemihydrate, paroxetine
Hydrochloride, hemihydrate paroxetine
|
Hydrochloride, paroxetine
I14-7752
KBio1_001828
KBio2_002232
KBio2_004800
KBio2_007368
KBioSS_002232
LS-114249
Maleate, paroxetine
MolPort-003-849-791
Motivan
NCGC00025355-02
NCGC00025355-03
NCGC00025355-04
NCGC00025355-05
NCGC00025355-06
NCGC00025355-07
NCGC00025355-08
NNC-20-7051
Paroxetina
Paroxetina [INN-Spanish]
paroxetine
Paroxetine
Paroxetine (TN)
Paroxetine (USP/INN)
Paroxetine [USAN:INN:BAN]
Paroxetine acetate
Paroxetine Hcl
Paroxetine hydrochloride
Paroxetine hydrochloride anhydrous
Paroxetine hydrochloride hemihydrate
Paroxetine hydrochloride, hemihydrate
Paroxetine maleate
Paroxetine, cis-(-)-isomer
Paroxetine, cis-(+)-isomer
Paroxetine, trans-(+)-isomer
Paroxetinum
Paroxetinum [INN-Latin]
Paxetil
Paxil
Paxil CR
PaxPar
Pexeva
Prestwick3_000851
Seroxat
Seroxat CR
SpecPlus_000788
Spectrum_001752
Spectrum5_001665
TL8003967
UNII-41VRH5220H
|
|
23 |
|
Fluoxetine |
Approved, Vet_approved |
Phase 3 |
|
54910-89-3 |
3386 |
Synonyms:
(+) or (-)-N-Methyl-3-phenyl-3-((alpha,alpha,alpha-trifluoro-p-tolyl)oxy)propylamine
(+) or (-)-N-Methyl-gamma-(4-(trifluoromethyl)phenoxy)benzenepropanamine
(+-)-N-Methyl-3-phenyl-3-((alpha,alpha,alpha-trifluoro-p-tolyl)oxy)propylamine
(+-)-N-Methyl-3-phenyl-3-((alpha,alpha,alpha-trifluoro-P-tolyl)oxy)propylamine
(+-)-N-Methyl-gamma-(4-(trifluoromethyl)phenoxy)benzenepropanamine
(+/-)-Fluoxetine
(+/-)-N-Methyl-3-(p-trifluoromethylphenoxy)-3-phenylpropylamine
(+/-)-N-Methyl-3-p-(p-trifluoromethylphenoxy)-3-phenylpropylamine
(+/-)-N-Methyl-3-phenyl-3-[(alpha,alpha,alpha-trifluoro-p-tolyl)oxy]propylamine
(+/-)-N-Methyl-3-phenyl-3-[4-(trifluoromethyl)phenoxy]propylamine]
(+/-)-N-Methyl-gamma-[4-(trifluoromethyl)phenoxy]benzenepropanamine
3-(p-Trifluoromethylphenoxy)-N-methyl-3-phenylpropylamine
52341-67-0
54910-89-3
57226-07-0
59333-67-4 (hydrochloride)
AB00053774
AC-14564
AC1L1FTH
Adofen
AKOS003663021
Animex-On
Bio-0787
Biomol-NT_000152
BPBio1_000354
BPBio1_000509
BRD-A31159102-001-01-9
BRD-A31159102-003-05-6
BSPBio_000461
BSPBio_003375
C17H18F3NO
CHEBI:5118
CHEMBL41
CID3386
D00326
DB00472
Deprex
DivK1c_006819
dl-3-(p-Trifluoromethylphenoxy)-N-methyl-3-phenylpropylamine
Eufor
Floxetine
Fluctin
Fluoxeren
Fluoxetin
Fluoxetina
Fluoxetina [INN-Spanish]
Fluoxetina [Spanish]
fluoxetine
Fluoxetine
Fluoxétine
fluoxetine (Prozac)
Fluoxetine (TN)
Fluoxetine (USAN/INN)
Fluoxetine [USAN:INN:BAN]
Fluoxetine Hcl
|
Fluoxetine hydrochloride
Fluoxetine Hydrochloride
Fluoxetinum
Fluoxetinum [INN-Latin]
Fluval
Fontex
Foxetin
HMS2090H14
KBio1_001763
KBio2_002159
KBio2_004727
KBio2_007295
KBio3_002595
KBioGR_001166
KBioSS_002159
L000931
Lilly-110140
Lopac0_000558
LS-31040
Methyl({3-phenyl-3-[4-(trifluoromethyl)phenoxy]propyl})amine
Methyl-[3-phenyl-3-(4-trifluoromethyl-phenoxy)-propyl]-amine
MolPort-001-683-482
NCGC00015428-10
NCGC00024879-03
NCGC00024879-04
nchembio.534-comp2
N-Methyl-3-(p-trifluoromethylphenoxy)-3-phenylpropylamine
N-methyl-3-phenyl-3-[4-(trifluoromethyl)phenoxy]propan-1-amine
N-methyl-3-phenyl-3-{[4-(trifluoromethyl)phenyl]oxy}propan-1-amine
N-Methyl-gamma-(4-(trifluoromethyl)phenoxy)benzenepropanamine
NSC283480
Portal
Prestwick0_000511
Prestwick1_000511
Prestwick2_000511
Prestwick3_000511
Prozac
Prozac Weekly
Pulvules
Reconcile
Reneuron
Sarafem
SPBio_001815
SPBio_002382
SpecPlus_000723
Spectrum_001679
Spectrum2_001658
Spectrum3_001648
Spectrum4_000613
Spectrum5_001518
STK734483
Symbyax
TL8003595
UNII-01K63SUP8D
|
|
24 |
|
Olanzapine |
Approved, Investigational |
Phase 3 |
|
132539-06-1 |
4585 |
Synonyms:
132539-06-1
2-methyl-4-(4-methyl-1-piperazinyl)-10 H -thieno[2,3- b ] [1,5]benzodiazepine
2-Methyl-4-(4-methyl-1-piperazinyl)-10H-thieno(2,3-b)(1,5)benzodiazepine
2-methyl-4-(4-methyl-1-piperazinyl)-10H-thieno[2,3-b][1,5]benzodiazepine
2-Methyl-4-(4-methyl-1-piperazinyl)-10H-thieno[2,3-b][1,5]benzodiazepine
2-methyl-4-(4-methylpiperazin-1-yl)-10H-thieno[2,3-b][1,5]benzodiazepine
2-methyl-4-(4-methylpiperazin-1-yl)-5H-thieno[2,3-b][1,5]benzodiazepine
2-methyl-4-(4-methylpiperazin-1-yl)-5H-thieno[3,2-c][1,5]benzodiazepine
AC1L1IHS
AC-665
AKOS000282888
ALKS-7921
BIDD:GT0332
BIDD:PXR0138
Bio-0169
C07322
C076029
C17H20N4S
CHEBI:7735
CHEMBL715
CID4585
CPD000466345
D00454
DB00334
Eli Lilly brand of olanzapine
HMS2051H05
HMS2089M04
HMS2093I04
I06-0784
InChI=1/C17H20N4S/c1-12-11-13-16(21-9-7-20(2)8-10-21)18-14-5-3-4-6-15(14)19-17(13)22-12/h3-6,11,19H,7-10H2,1-2H
InChI=1/C17H20N4S/c1-12-11-13-16(21-9-7-20(2)8-10-21)18-14-5-3-4-6-15(14)19-17(13)22-12/h3-6,11,19H,7-10H2,1-2H3
Jsp001969
KS-1090
L000455
L005958
Lanzac
Lilly brand of olanzapine
LS-152313
LY 170053
LY-170052
|
LY-170053
Midax
MLS000759457
MLS001165781
MLS001195646
MLS001424057
MolPort-002-885-845
MolPort-003-666-569
MolPort-005-977-341
NCGC00096077-01
NCGC00096077-03
NCGC00096077-04
Olansek
Olanzapin
olanzapina
Olanzapina
olanzapine
Olanzapine
Olanzapine (JAN/USAN/INN)
Olanzapine (OLA)
Olanzapine [USAN:INN]
olanzapinum
Olanzapinum
S2493_Selleck
SAM001246652
SMR000466345
SPECTRUM1505024
STK634338
Symbyax
TL8000772
UNII-N7U69T4SZR
Zalasta
Zydis
Zyprexa
Zyprexa (TN)
Zyprexa intramuscular
Zyprexa Intramuscular
Zyprexa Velotab
Zyprexa zydis
Zyprexa Zydis
|
|
25 |
|
Minocycline |
Approved, Investigational |
Phase 3 |
|
10118-90-8 |
5281021 |
Synonyms:
(2Z,4S,4aS,5aR,12aS)-2-[amino(hydroxy)methylidene]-4,7-bis(dimethylamino)-10,11,12a-trihydroxy-4a,5,5a,6-tetrahydro-4H-tetracene-1,3,12-trione
(4S,4aS,5aR,12aS)-4,7-bis(dimethylamino)-3,10,12,12a-tetrahydroxy-1,11-dioxo-1,4,4a,5,5a,6,11,12a-octahydrotetracene-2-carboxamide
(4S,4AS,5ar,12as)-4,7-bis(dimethylamino)-3,10,12,12a-tetrahydroxy-1,11-dioxo-1,4,4a,5,5a,6,11,12a-octahydrotetracene-2-carboxamide
(4S,4AS,5AR,12AS)-4,7-BIS(DIMETHYLAMINO)-3,10,12,12A-TETRAHYDROXY-1,11-DIOXO-1,4,4A,5,5A,6,11,12A-OCTAHYDROTETRACENE-2-CARBOXAMIDE
10118-90-8
13614-98-7 (mono-hydrochloride)
4,7-Bis(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,10,12,12a-tetrahydroxy-1,11-dioxo-2-naphthacenecarboxamide
4708-96-7
7-dimethylamino-6-Demethyl-6-deoxytetracycline
7-Dimethylamino-6-demethyl-6-deoxytetracycline
AC1NQXWM
Alti-Minocycline
Apo-Minocycline
Arestin
Bio-0062
Borymycin
BRN 3077644
C07225
C23H27N3O7
CHEBI:50694
CHEBI:529981
CHEMBL1434
CHEMBL259172
CID5281021
CL 59806
CRL-1605 & Minocycline
D05045
Dynacin
Gen-Minocycline
HMS2090D03
HSDB 3130
Klinomycin
Lactoferrin B & Minocycline
|
Lactoferrin H & Minocycline
LMPK07000002
LS-93850
MINO
Minociclina
Minociclina [INN-Spanish]
minociclinum
Minociclinum
Minocin
Minocin (Hydrochloride)
Minocline
Minocyclin
minocycline
Minocycline
Minocycline (USAN/INN)
Minocycline [USAN:BAN:INN]
Minocycline HCl
Minocycline Monohydrochloride
Minocyclinum
Minocyclinum [INN-Latin]
Minocyn
Minomycin
MIY
NCGC00178854-01
nchembio.559-comp1
Novo-Minocycline
NSC 141993
NSC141993
Solodyn
UNII-FYY3R43WGO
Vectrin
Vectrin (Hydrochloride)
|
|
26 |
|
Dopamine Antagonists |
|
Phase 3 |
|
|
|
27 |
|
Antipsychotic Agents |
|
Phase 3 |
|
|
|
28 |
|
Adrenergic Agents |
|
Phase 3 |
|
|
|
29 |
|
Gastrointestinal Agents |
|
Phase 3 |
|
|
|
30 |
|
Antiemetics |
|
Phase 3 |
|
|
|
31 |
|
Tiapride Hydrochloride |
|
Phase 3 |
|
|
|
32 |
|
Serotonin Uptake Inhibitors |
|
Phase 3 |
|
|
|
33 |
|
Serotonin |
Investigational, Nutraceutical |
Phase 3 |
|
50-67-9 |
5202 |
Synonyms:
3-(2-Aminoethyl)-1H-indol-5-ol
3-(2-Aminoethyl)indol-5-ol
3-(b-Aminoethyl)-5-hydroxyindole
5 Hydroxytryptamine
5-HT
5-HTA
5-Hydroxy-3-(b-aminoethyl)indole
5-Hydroxyltryptamine
5-Hydroxytriptamine
5-Hydroxytryptamine
5-Hydroxy-tryptamine
Antemovis
|
DS Substance
Enteramin
Enteramine
Hippophaine
Hydroxytryptamine
Serotonine
sérotonine
thrombocytin
Thrombocytin
thrombotonin
Thrombotonin
|
|
34 |
|
Citalopram |
Approved |
Phase 2 |
|
59729-33-8 |
2771 |
Synonyms:
[3H]Citalopram
1-(3-(Dimethylamino)propyl)-1-(p-fluorophenyl)-5-phthalancarbonitrile
1,3-dihydro[3,4]benzofuran-5-carbonitrile
1,3-Dihydro-1-(3-(dimethylamino)propyl)-1-(4-fluorophenyl)-5-isobenzofurancarbonitrile
1-[3-(dimethylamino)propyl]-1-(4-fluorophenyl)-1,3-dihydro-2-benzofuran-5-carbonitrile
1-[3-(dimethylamino)propyl]-1-(4-fluorophenyl)-3H-2-benzofuran-5-carbonitrile
59729-33-8
AB00513896
AC-12214
AC1L1EFH
AE-641/00603021
Akarin
Bonitrile
BPBio1_000929
BRD-A47598013-004-02-0
BSPBio_000843
C07572
C20H21FN2O
Celapram
Celexa
Celius
CHEBI:3723
CHEMBL549
Ciazil
CID2771
Cilift
Cipram
Cipramil
Ciprapine
Citabax
Citadur
Citadur (TN)
Citalec
citalopram
Citalopram
Citalopram (USP/INN)
Citalopram [Celexa]
Citalopram [INN:BAN]
Citalopram hydrobromide
Citalopram Hydrobromide
Citalopramum
Citalopramum [INN-Latin]
|
Citol
Citopam
Citox
Citrol
CPD000465669
Cytalopram
D07704
Dalsan
DB00215
EINECS 261-891-1
Elopram
Escitalopram
HMS2090O09
HMS2093A14
Humorup
I01-0382
InChI=1/C20H21FN2O/c1-23(2)11-3-10-20(17-5-7-18(21)8-6-17)19-9-4-15(13-22)12-16(19)14-24-20/h4-9,12H,3,10-11,14H2,1-2H3
L001223
Lexapro
Lopac0_000258
LS-84327
Lu 10-171
Lu-10-171
MolPort-003-666-794
NCGC00015267-07
NCGC00025160-02
Nitalapram
Oropram
Pramcit
Prestwick3_000692
Recital
SAM002589960
Seropram
ST069372
STL058639
Talam
Talohexal
Temperax
UNII-0DHU5B8D6V
Vodelax
Zentius
Zetalo
|
|
35 |
|
Histamine |
Approved, Investigational |
Phase 2 |
|
51-45-6 |
774 |
Synonyms:
1H-Imidazole-4-ethanamine
2-(1H-Imidazol-4-yl)ethanamine
2-(1H-Imidazol-4-yl)ethylamine
2-(1H-Imidazol-5-yl)ethanamine
2-(1H-Imidazol-5-yl)ethylamine
2-(4-Imidazolyl)ethanamine
2-(4-imidazolyl)ethylamine
2-(4-Imidazolyl)ethylamine
2-Imidazol-4-ylethylamine
2-Imidazol-4-yl-ethylamine
4-(2-Aminoethyl)-1H-imidazole
4-(2-Aminoethyl)imidazole
4-imidazoleethylamine
4-Imidazoleethylamine
5-imidazoleethylamine
5-Imidazoleethylamine
beta-aminoethylglyoxaline
beta-Aminoethylglyoxaline
beta-aminoethylimidazole
|
beta-Aminoethylimidazole
beta-Aminothethylglyoxaline
beta-Imidazolyl-4-ethylamine
b-Imidazolyl-4-ethylamine
Ceplene
Dihydrochloride, histamine
Eramin
Ergamine
Ergotidine
Free histamine
Histamine dihydrochloride
Histamine hydrochloride
HSM
Hydrochloride, histamine
L-Histamin base
L-Histamine
Peremin
Theramine
|
|
36 |
|
Famotidine |
Approved |
Phase 2 |
|
76824-35-6 |
3325 |
Synonyms:
(1-amino-3-(((2-((Diaminomethylene)amino)-4-thiazolyl)methyl)thio)propylidene)sulfamide
(1-Amino-3-(((2-((diaminomethylene)amino)-4-thiazolyl)methyl)thio)propylidene)sulfamide
(1-amino-3-(((2-((Diaminomethylene)amino)-4-thiazolyl)methyl)thio)propylidene)sulphamide
(1Z)-3-[({2-[(diaminomethylidene)amino]-1,3-thiazol-4-yl}methyl)sulfanyl]-N'-sulfamoylpropanimidamide
(1Z)-N'-(aminosulfonyl)-3-[({2-[(diaminomethylidene)amino]-1,3-thiazol-4-yl}methyl)thio]propanimidamide
3-(((2-((Aminoiminomethyl)amino)-4-thiazolyl)methyl)thio)-N-(aminosulfonyl)propanimidamide
3-(((2-((Aminoiminomethyl)amino)-4-thiazolyl)methyl)thio)-N-(aminosulphonyl)propanimidamide
3-(((2-((Diaminomethylene)amino)-4-thiazolyl)methyl)thio)-N(sup 2)-sulfamoylpropionamidine
3-(2-Guanidinothiazol-4-ylmethylthio)-N1-sulfamoylpropionamide
3-[({2-[(diaminomethylidene)amino]-1,3-thiazol-4-yl}methyl)sulfanyl]-N-sulfamoylpropanimidamide
3-[[2-(diaminomethylideneamino)-1,3-thiazol-4-yl]methylsulfanyl]-N'-sulfamoylpro
3-[[2-(diaminomethylideneamino)-1,3-thiazol-4-yl]methylsulfanyl]-N'-sulfamoylpropanimidamide
76824-35-6
AC-11713
AC1NWASH
AC1Q50E0
AC1Q50E1
Amfamox
Antodine
apo-Famotidine
Apo-Famotidine
Apogastine
Bestidine
BIDD:GT0759
Bio-0739
Blocacid
BPBio1_000098
Brolin
BSPBio_000088
C8H15N7O2S3
CAS-76824-35-6
Cepal
CHEBI:4975
CHEMBL902
CID5702160
Confobos
CPD000058961
Cronol
Cuantin
DB00927
Dibrit 40
Digervin
Dinul
Dipsin
Dispromil
Dispronil
Duovel
Durater
EU-0100497
Evatin
F 6889
F0530
F6889_SIGMA
Fadin
Fadine
Fadyn
Fagastine
Famo
Famocid
Famodar
Famodil
Famodin
Famodine
Famogard
Famonit
Famopsin
Famos
Famosan
Famotal
Famotep
Famotidina
Famotidina [Spanish]
famotidine
Famotidine
Famotidine [USAN:BAN:INN:JAN]
Famotidine hydrochloride
FAMOTIDINE PRESERVATIVE FREE
FAMOTIDINE PRESERVATIVE FREE IN PLASTIC CONTAINER
Famotidinum
Famotidinum [Latin]
Famotin
Famovane
Famowal
Famox
Famoxal
Famtac
Famulcer
Fanobel
Fanosin
Fanox
Farmotex
Ferotine
Fibonel
Fluxid
Fudone
Ganor
Gaster
Gastridan
Gastridin
Gastrion
Gastro
Gastrodomina
Gastrofam
Gastropen
Gastrosidin
H2 Bloc
Hacip
HMS1568E10
HMS2051A07
HMS2089I12
|
HS-0054
HSDB 3572
Huberdina
InChI=1/C8H15N7O2S3/c9-6(15-20(12,16)17)1-2-18-3-5-4-19-8(13-5)14-7(10)11/h4H,1-3H2,(H2,9,15)(H2,12,16,17)(H4,10,11,13,14)
Ingastri
Invigan
L 643341
L003830
L013386
Lecedil
Logos
Lopac0_000497
Lopac-F-6889
LS-121117
Mensoma
Midefam
MK 208
MK-208
MLS000028583
MLS000758205
MLS001423994
MolPort-002-557-620
MolPort-003-941-395
Mosul
Motiax
Muclox
Mylanta ar
Mylanta AR
N'-(Aminosulfonyl)-3-([2-(diaminomethyleneamino)-4-thiazolyl]methylthio)propanamidine
NCGC00015446-01
NCGC00015446-02
NCGC00015446-03
NCGC00015446-06
NCGC00018276-01
NCGC00018276-02
NCGC00093899-01
NCGC00093899-02
NCGC00093899-03
Neocidine
Nevofam
Notidin
novo-Famotidine
Novo-Famotidine
N-Sulfamoyl-3-((2-guanidinothiazol-4-yl)methylthio)propionamide
N-Sulphamoyl-3-((2-guanidinothiazol-4-yl)methylthio)propionamide
Nu-Famotidine
Nulceran
Nulcerin
Panalba
PDSP1_000398
PDSP2_000396
Pepcid
PEPCID
Pepcid AC
Pepcid AC Gelcaps
PEPCID COMPLETE
PEPCID PRESERVATIVE FREE
PEPCID PRESERVATIVE FREE IN PLASTIC CONTAINER
Pepcid RPD
Pepcidac
Pepcidin
Pepcidin pepcidine
Pepcidin Rapitab
Pepcidina
Pepcidine
Pepdif
Pepdine
Pepdul
Pepfamin
Peptan
Peptidin
Peptifam
Pepzan
Prestwick_212
Prestwick2_000104
Prestwick3_000104
Propanimidamide, 3-[[[2-[aminoiminomethyl)amino]-4-thiazoyl]methyl]thio]-N-(aminosulfonyl)
Purifam
Quamatel
Quamtel
Renapepsa
Restadin
Rogasti
Rubacina
SAM001247033
Sedanium-R
Sigafam
SMR000058961
STK527689
Supertidine
Tairal
Tamin
Tipodex
TL8005267
Topcid
Ulcatif
Ulceprax
Ulcofam
Ulfagel
Ulfam
Ulfamid
Ulfinol
Ulgarine
Vagostal
Weimok
Whitidin
Yamarin
YM 11170
YM-11170
YM-1170
|
|
37 |
|
Trihexyphenidyl |
Approved |
Phase 2 |
|
144-11-6, 58947-95-8 |
5572 |
Synonyms:
(+-)-alpha-Cyclohexyl-alpha-phenyl-1-piperidinepropanol hydrochloride
144-11-6
144-11-6 (Parent)
1-cyclohexyl-1-phenyl-3-piperidin-1-ylpropan-1-ol
1-cyclohexyl-1-phenyl-3-piperidin-1-ylpropan-1-ol hydrochloride
1-Phenyl-1-cyclohexyl-3-piperidyl-1-propanol hydrochloride
1-Piperidinepropanol, alpha-cyclohexyl-alpha-phenyl-, hydrochloride
3-(1-Piperidyl)-1-cyclohexyl-1-phenyl-1-propanol hydrochloride
5-20-02-00231 (Beilstein Handbook Reference)
52-49-3
52-49-3 (hydrochloride)
58947-95-8
AB00053559
AC1L1KNB
AC1L24EZ
AC-4520
AHP brand OF trihexyphenidyl hydrochloride
alpha-Cyclohexyl-alpha-phenyl-1-piperidinepropanol hydrochloride
apo Trihex
Apotex brand OF trihexyphenidyl hydrochloride
apo-Trihex
ApoTrihex
Apo-Trihex
Apo-trihex (TN)
Artane
Artane (TN)
Artane hydrochloride
Artane Sequels
Aventis brand OF trihexyphenidyl hydrochloride
Benzhexol
Benzhexol chloride
Benzhexol hydrochloride
Benzhexolum
BPBio1_000971
BRD-A48180038-003-05-2
BRN 0088959
BSPBio_000881
BSPBio_002930
C07171
C20H31NO
CHEMBL1092
CHEMBL1490
CID5572
CID66007
CPD000058515
Cyclodol
Cyclodolum
Cypress brand OF trihexyphenidyl hydrochloride
D00787
D08638
DB00376
DivK1c_000372
DL-TRIHEXYPHENIDYL
DL-TRIHEXYPHENIDYL HYDROCHLORIDE
EINECS 200-142-5
EINECS 205-614-4
Eisai brand OF trihexyphenidyl hydrochloride
EU-0101125
Hexal brand OF trihexyphenidyl hydrochloride
Hipokinon
HMS1570M03
HMS1921G17
HSDB 3196
IDI1_000372
KBio1_000372
KBio2_001112
KBio2_003680
KBio2_006248
KBio3_002150
KBioGR_000837
KBioSS_001112
L000821
Lederle brand OF trihexyphenidyl hydrochloride
Liquipharm brand OF trihexyphenidyl hydrochloride
Lopac0_001125
LS-116010
LS-116011
LS-116014
MLS000069670
MLS001148658
MolPort-001-783-510
|
MolPort-003-666-299
NCGC00016003-06
NCGC00089797-02
NCGC00094393-01
NCGC00094393-02
NCGC00094393-03
NCGC00094393-04
NCGC00094393-05
NINDS_000372
NSC 12268
NSC12268
Oprea1_853391
Pacitane
Paralest
Parcopane
Pargitan
Parkinane
Parkinane retard
Parkopan
Peragit
Pharmaceutical associates brand OF trihexyphenidyl hydrochloride
Pipanol
PMS Trihexyphenidyl
Prestwick_133
Prestwick0_000701
Prestwick1_000701
Prestwick2_000701
Prestwick3_000701
Psicofarma brand OF trihexyphenidyl hydrochloride
Romparkin
Rugby brand OF trihexyphenidyl hydrochloride
SAM002264652
Schrein brand OF trihexyphenidyl hydrochloride
Sedrena (free base)
SMR000058515
SPBio_000757
SPBio_002802
Spectrum_000632
SPECTRUM1500592
Spectrum2_000829
Spectrum3_001375
Spectrum4_000369
Spectrum5_001465
ST51015131
T 1516
T1516_SIGMA
TL8003459
Tremin
Triesifenidile
Triexifenidila
Trihexane
Trihexidyl hydrochloride
Trihexifenidilo
Trihexifenidilo [INN-Spanish]
Trihexy
Trihexylphenidyl
Trihexylphenidyle
Trihexylphenizyl
trihexyphenidyl
Trihexyphenidyl
Trihexyphenidyl (INN)
Trihexyphenidyl [INN:BAN]
Trihexyphenidyl HCl
Trihexyphenidyl hydrochloride
Trihexyphenidyl hydrochloride (JP15/USP)
Trihexyphenidyl hydrochloride [JAN]
Trihexyphenidyl hydrochloride elixir
Trihexyphenidyl wyeth brand
Trihexyphenidyl-D,L Hydrochloride
Trihexyphenidyle
Trihexyphénidyle
Trihexyphenidyle [INN-French]
Trihexyphenidylum
Trihexyphenidylum [INN-Latin]
Triphenidyl
Tsiklodol
UNII-6RC5V8B7PO
UNII-AO61G82577
WIN 511
Wyeth brand OF trihexyphenidyl
Wyeth brand OF trihexyphenidyl hydrochloride
|
|
38 |
|
Risperidone |
Approved, Investigational |
Phase 2 |
|
106266-06-2 |
5073 |
Synonyms:
106266-06-2
3-(2-(4-(6-Fluoro-1,2-benzisoxazol-3-yl)piperidino)ethyl)-6,7,8,9-tetrahydro-2-methyl-4H-pyrido(1,2-a)pyrimidin-4-one
3-(2-[4-(6-fluoro-benzo[d]isoxazol-3-yl)-piperidin-1-yl]-ethyl)-2-methyl-6,7,8,9-tetrahydro-pyrido[
3-(2-[4-(6-fluoro-benzo[d]isoxazol-3-yl)-piperidin-1-yl]-ethyl)-2-methyl-6,7,8,9-tetrahydropyrido[1,
3-[2-[4-(6-Fluoro-1,2-benzisoxazol-3-yl)-1-piperidinyl]-6,7,8,9-tetrahydro-2-methyl-4H-pyrido [1,2-a] pyrimidin-4-one
3-[2-[4-(6-fluoro-1,2-benzisoxazol-3-yl)-1-piperidinyl]ethyl]-6,7,8,9-tetrahydro-2-methyl-4H-pyrido[1,2-a]pyrimidin-4-one
3-[2-[-4-(6-fluoro-1,2-benzisoxazol-3-yl)-1-piperidinyl]ethyl]-6,7,8,9-tetrahydro-2-methyl-4H-pyrido[1,2-a]pyrimidin-4-one
3-[2-[4-(6-Fluoro-1,2-benzisoxazol-3-yl)piperi-dino]ethyl]-6,7,8,9-tetrahydro-2-methyl-4H-pyrido[1,2-a]-pyrimidin-4-one
3-[2-[4-(6-fluoro-1,2-benzoxazol-3-yl)piperidin-1-yl]ethyl]-2-methyl-6,7,8,9-tetrahydropyrido[1,2-a]pyrimidin-4-one
3-[2-[4-(6-fluoro-benzo[d]isoxazol-3-yl)-piperidin-1-yl]-ethyl]-2-methyl-6,7,8,9-tetrahydropyrido[1,
3-{2-[4-(6-fluoro-1,2-benzisoxazol-3-yl)piperidin-1-yl]ethyl}-2-methyl-6,7,8,9-tetrahydro-4H-pyrido[1,2-a]pyrimidin-4-one
3-{2-[4-(6-fluoro-1,2-benzoxazol-3-yl)piperidin-1-yl]ethyl}-2-methyl-6,7,8,9-tetrahydro-4H-pyrido[1,2-a]pyrimidin-4-one
3-{2-[4-(6-Fluoro-benzo[d]isoxazol-3-yl)-piperidin-1-yl]-ethyl}-2-methyl-6,7,8,9-tetrahydropyrido[1,2-a]pyrimidin-4-one
AB00514010
AC-1306
AC1L1JJU
Belivon
BIDD:GT0262
Bio-0092
BRD-K53857191-001-04-5
BRN 4891881
Buspirone
C23H27FN4O2
CAS-106266-06-2
CHEBI:8871
CHEMBL85
CID5073
Consta, risperdal
Consta, Risperdal
CPD000466323
D00426
D018967
DB00734
EU-0101074
HMS1571M19
HMS2051H07
HMS2089C22
HSDB 7580
I01-1156
Jsp000573
KS-1106
L000510
Lopac-R-118
LS-134196
MLS000759429
MLS001165758
MLS001424081
MolPort-002-885-858
NCGC00015883-01
NCGC00015883-02
|
NCGC00015883-03
NCGC00094352-01
NCGC00094352-02
NCGC00094352-03
NCGC00179257-01
Prestwick0_001029
Prestwick1_001029
R 62 766
R 64 766, Risperdal, Risperidone
R 64,766
R 64766
R-118
R64,766
R-64,766
R64766
R-64766
R-64-766
Rispen
Risperdal
Risperdal (TN)
Risperdal consta
Risperdal Consta
Risperdal m-tab
Risperdal M-Tab
risperdone
Risperidal
Risperidal M-Tab
Risperidona
Risperidona [Spanish]
risperidone
Risperidone
Rispéridone
Risperidone (JAN/USAN/INN)
Risperidone (RIS)
Risperidone [USAN:BAN:INN]
Risperidone, placebo
Risperidonum
Risperidonum [Latin]
Risperin
Rispolept
Rispolin
S1615_Selleck
SAM001246595
Sequinan
SMR000466323
SPBio_003078
Spiron
STK646402
TL8000230
UNII-L6UH7ZF8HC
|
|
39 |
|
Natalizumab |
Approved, Investigational |
Phase 1, Phase 2 |
|
189261-10-7 |
|
Synonyms:
189261-10-7
Anti-alpha4 integrin
Anti-VLA4
D06886
|
Natalizumab
Natalizumab (INN)
Tysabri
Tysabri (TN)
|
|
40 |
|
Glutamic acid |
Approved, Nutraceutical |
Phase 2 |
|
56-86-0 |
33032 |
Synonyms:
(2S)-2-Aminopentanedioate
(2S)-2-Aminopentanedioic acid
(S)-(+)-Glutamate
(S)-(+)-Glutamic acid
(S)-2-Aminopentanedioate
(S)-2-Aminopentanedioic acid
(S)-Glutamate
(S)-Glutamic acid
09581_FLUKA
10549-13-0
138-15-8 (unspecified hydrochloride)
138-16-9
16690-92-9 (di-hydrochloride salt)
19238-49-4 (unspecified calcium salt)
19473-49-5 (mono-potassium salt)
1-amino-Propane-1,3-dicarboxylate
1-Aminopropane-1,3-dicarboxylate
1-amino-Propane-1,3-dicarboxylic acid
1-Aminopropane-1,3-dicarboxylic acid
1ftj
1ii5
1xff
24595-14-0 (unspecified potassium salt)
24938-00-9
25513-46-6
26717-13-5
27322E29-9696-49C1-B541-86BEF72DE2F3
2-Aminoglutarate
2-Aminoglutaric acid
2-Aminopentanedioate
2-aminopentanedioic acid
2-Aminopentanedioic acid
49449_FLUKA
49449_SIGMA
55695-80-2 (mono-lithium salt)
56-86-0
6899-05-4
7558-63-6 (mono-ammonium salt)
84960-48-5
a-Aminoglutarate
a-Aminoglutaric acid
AB1002631
AC-11294
AC1L1OVN
AC1Q28OF
AC1Q4U8B
AC1Q4U8C
Acide glutamique
Acide glutamique [INN-French]
acido Glutamico
Acido glutamico
ácido glutámico
Acido glutamico [INN-Spanish]
Acidum glutamicum
Acidum glutamicum [INN-Latin]
Acidum glutaminicum
Aciglut
a-Glutamate
a-Glutamic acid
AI3-18472
alpha-Aminoglutarate
alpha-aminoglutaric acid
alpha-Aminoglutaric acid
alpha-Aminoglutaric acid (VAN)
alpha-Glutamate
alpha-Glutamic acid
alpha-L-Glutamic acid polymer
Aluminum L glutamate
Aluminum L-glutamate
AmbotzHAA1087
Aminoglutarate
Aminoglutaric acid
Biomol-NT_000170
BPBio1_001132
C00025
CCRIS 7314
CHEBI:16015
CHEMBL575060
CID33032
D Glutamate
D00007
DB00142
DB02517
D-Glutamate
D-Glutamiensuur
E
E 620
EINECS 200-293-7
EPA Pesticide Chemical Code 374350
FEMA No. 3285
|
FT-0085107
G0059
G1251_SIGMA
G5667_SIGMA
G8415_SIGMA
Glt
glu
Glu
Glusate
glut
Glut
glutacid
Glutacid
glutamate
Glutamate
Glutamate, potassium
Glutamic acid
GLUTAMIC ACID
Glutamic acid (H-3)
Glutamic Acid (L-glutamic acid)
Glutamic acid (VAN)
Glutamic Acid [USAN:INN]
Glutamic acid polymer
Glutamic acid, (D)-isomer
Glutamic acid, L- (7CI,8CI)
Glutamic acid, L-, peptides
Glutamicol
Glutamidex
Glutaminate
glutaminic acid
Glutaminic acid
Glutaminic acid (VAN)
Glutaminol
Glutaton
Gulutamine
Gulutamine (USP)
H-Glu-OH
HSCI1_000269
L Glutamate
L Glutamic acid
L-(+)-Glutamate
L-(+)-glutamic acid
L-(+)-Glutamic acid
L-2-Aminoglutaric acid
L-a-Aminoglutarate
L-a-Aminoglutaric acid
L-alpha-Aminoglutarate
L-alpha-Aminoglutaric acid
L-glu
L-Glu
L-glutamate
L-Glutamate
L-Glutamate, aluminum
L-glutamic acid
L-Glutamic acid
L-Glutamic acid (9CI)
L-Glutamic acid (JAN)
L-Glutamic acid hydrochloride
L-Glutamic acid, homopolymer
L-Glutamic acid, homopolymer (9CI)
L-Glutaminate
L-Glutaminic acid
L-Glutaminsaeure
Lopac0_000529
LS-2330
LS-71885
MolPort-001-770-254
NCGC00024502-01
NCGC00024502-02
NCGC00024502-03
NCGC00024502-04
nchembio.186-comp9
nchembio.198-comp6
nchembio.2007.55-comp22
nchembio.266-comp23
nchembio.586-comp22
nchembio816-comp2
NSC 143503
PDSP1_000128
PDSP1_001539
PDSP2_000127
PDSP2_001523
Poly(alpha-L-glutamic acid)
POLYGLUTAMIC ACID
Poly-L-glutamate
Potassium glutamate
Sodium Glutamate (L-glutamic Acid)
Tocris-0218
UNII-3KX376GY7L
W328502_ALDRICH
|
|
41 |
|
Excitatory Amino Acid Antagonists |
|
Phase 2 |
|
|
|
42 |
|
Anti-Bacterial Agents |
|
Phase 2 |
|
|
|
43 |
|
penicillins |
|
Phase 2 |
|
|
|
44 |
|
Atomoxetine Hydrochloride |
|
Phase 2 |
|
|
|
45 |
|
Antacids |
|
Phase 2 |
|
|
|
46 |
|
Anti-Ulcer Agents |
|
Phase 2 |
|
|
|
47 |
|
Histamine Antagonists |
|
Phase 2 |
|
|
|
48 |
|
Histamine Phosphate |
|
Phase 2 |
|
51-74-1 |
65513 |
Synonyms:
1H-Imidazole-4-ethanamine, phosphate (1:2)
2-Imidazol-4-ylethylamine orthophosphoric acid (1:2)
4-(2-Aminoethyl)imidazole bis(dihydrogen phosphate)
4-(2-Aminoethyl)imidazole di-acid phosphate
4-2(2-Aminoethyl)Imidazole-Di-Acid Phosphate
51-74-1
53623-99-7
74-56-6
AC1L23E4
CID65513
D04445
DB00667
EINECS 200-118-4
|
H0147
Histamine acid phosphate
Histamine biphosphate
Histamine dihydrogen phosphate
Histamine diphosphate
Histamine phosphate (1:2)
Histamine phosphate (TN)
Histamine phosphate (USP)
Histamine phosphate [USP]
Histamine positive
LS-78569
UNII-QWB37T4WZZ
|
|
49 |
|
Histamine H2 Antagonists |
|
Phase 2 |
|
|
|
50 |
|
Cholinergic Agents |
|
Phase 2 |
|
|
|
Interventional clinical trials:
(show top 50)
(show all 66)
# |
Name |
Status |
NCT ID |
Phase |
Drugs |
1 |
Dopamine Treatment in Children With Cerebral Palsy With Dystonia- A Double Blind Controlled Study |
Unknown status |
NCT01361373 |
Phase 4 |
L- DOPA;placebo |
2 |
The Effect of Amantadine on Movement Disorder in Ataxia-Telangiectasia |
Completed |
NCT00950196 |
Phase 4 |
amantadine sulphate |
3 |
Different Dyskinesias in Parkinson's Disease and Their Relation to Levodopa Pharmacokinetics |
Completed |
NCT00888186 |
Phase 4 |
levodopa/carbidopa |
4 |
Adding Orally Disintegrating Selegiline (Zelapar) to Patients Taking Dopamine Agonists and Experiencing Complications |
Completed |
NCT00443872 |
Phase 4 |
orally disintegrating selegiline (Zelapar) |
5 |
A Randomized, Double-Blind, Placebo-Controlled Study of Tetrabenazine for the Treatment of Huntington's Chorea |
Completed |
NCT00219804 |
Phase 3 |
tetrabenazine or placebo |
6 |
An Open-Label, Long Term Safety Study of SD-809 ER in Subjects With Chorea Associated With Huntington Disease |
Completed |
NCT01897896 |
Phase 3 |
SD-809 |
7 |
A Randomized Double-Blind, Placebo-Controlled Study of SD-809 Extended Release for the Treatment of Chorea Associated With Huntington Disease |
Completed |
NCT01795859 |
Phase 3 |
SD-809;Placebo |
8 |
Neuroleptic and Huntington Disease. Comparison of : Olanzapine, la Tetrabenazine and Tiapride. A Multicentric, Randomised, Controlled Study. |
Completed |
NCT00632645 |
Phase 3 |
Olanzapine;Xenazine;Tiapridal |
9 |
Double-Blind, Randomised, Two-Armed Study for the Evaluation of Efficacy and Safety of Minocycline for Treatment |
Completed |
NCT00146809 |
Phase 3 |
Minocyline |
10 |
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy, Safety, and Tolerability of Valbenazine for the Treatment of Chorea Associated With Huntington Disease |
Recruiting |
NCT04102579 |
Phase 3 |
Valbenazine;Placebo |
11 |
A Randomized, Double-Blind, Placebo-Controlled Study of TEV-50717 (Deutetrabenazine) for the Treatment of Dyskinesia in Cerebral Palsy in Children and Adolescents |
Active, not recruiting |
NCT03813238 |
Phase 3 |
Deutetrabenazine;Placebo |
12 |
Open-Label Rollover Study for Continuing Valbenazine Administration for the Treatment of Chorea Associated With Huntington Disease |
Enrolling by invitation |
NCT04400331 |
Phase 3 |
Valbenazine |
13 |
Trial of Kuvan™ (Sapropterin) Treatment in Patients With Lesch Nyhan Disease |
Withdrawn |
NCT00935753 |
Phase 2, Phase 3 |
sapropterin |
14 |
Safety and Efficacy of Bone Marrow Derived MNCs for the Treatment of Huntingtons Chorea. It is Self Funded (Patients' Own Funding) Clinical Trial |
Unknown status |
NCT01834053 |
Phase 1, Phase 2 |
|
15 |
Phase IIa, Double-blind, Randomized, Placebo-controlled Study of the Efficacy and Safety of SOM3355 in Huntington's Disease (HD) Patients With Chorea Movements. |
Completed |
NCT03575676 |
Phase 2 |
SOM3355 100mg BID;SOM3355 200mg BID;Placebo BID |
16 |
NMDA-Receptor Blockade in Huntington's Chorea |
Completed |
NCT00001930 |
Phase 2 |
Amantadine |
17 |
A Multi-Center, North American, Open-Label Extension Study of Pridopidine (ACR16) in the Symptomatic Treatment of Huntington's Disease (Open-HART). |
Completed |
NCT01306929 |
Phase 2 |
pridopidine |
18 |
A Phase 2, Randomized, Placebo Controlled, Double Blind Proof-of-concept Study Of The Efficacy And Safety Of Pf-02545920 In Subjects With Huntington's Disease |
Completed |
NCT02197130 |
Phase 2 |
PF-02545920;PF-02545920 |
19 |
Atomoxetine for Attention Deficits in Adults With Mild HD: A Randomized, Placebo-Controlled Crossover Study |
Completed |
NCT00368849 |
Phase 2 |
atomoxetine;Matching Placebo |
20 |
A Randomized, Placebo-Controlled Pilot Study in Huntington's Disease (CIT-HD) |
Completed |
NCT00271596 |
Phase 2 |
20mg daily citalopram;Placebo |
21 |
An 'N-of-1' Study of the Histamine H@ Antagonist, Famotidine in Levodopa-induced Dyskinesia in Parkinson's Disease |
Completed |
NCT01937078 |
Phase 2 |
Famotidine |
22 |
Childhood Hypertonia of Central Origin: An Open Label Trial of Anticholinergic Treatment Effects |
Completed |
NCT00122044 |
Phase 2 |
trihexyphenidyl |
23 |
A Trial of Prophylaxis for the PANDAS Subgroup |
Completed |
NCT00001359 |
Phase 2 |
Penicillin or Placebo |
24 |
Risperidone for the Treatment of Huntington's Disease Chorea |
Not yet recruiting |
NCT04201834 |
Phase 2 |
Risperidone |
25 |
Clinical and Neurochemical Effects of Transcranial Magnetic Stimulation (TMS) in Multiple Sclerosis |
Not yet recruiting |
NCT04062331 |
Phase 1, Phase 2 |
Placebos |
26 |
A Multi-centre, Randomized, Double-blind, Placebo-controlled, Parallel-group, Multiple Oral Dose Titration Proof of Concept Study in Patients With Huntington's Disease to Assess the Efficacy, Safety and Tolerability of AFQ056 in Reducing Chorea |
Terminated |
NCT01019473 |
Phase 2 |
AFQ056;Placebo |
27 |
An Open Label Extension Study To Investigate The Long Term Safety, Tolerability And Efficacy Of Pf-02545920 In Subjects With Huntington's Disease Who Previously Completed Study A8241021 |
Terminated |
NCT02342548 |
Phase 2 |
20 mg BID of PF-02545920 |
28 |
Phase 1 Study to Determine the Efficacy of Using Far Infrared Radiation for Control, Management and Treatment of HD |
Unknown status |
NCT00675077 |
Phase 1 |
|
29 |
Ursodiol in Huntington's Disease |
Unknown status |
NCT00514774 |
Phase 1 |
ursodiol;placebo |
30 |
A Phase 1b, Open-label, Parallel-group Study in Subjects With Huntington Disease to Assess the Safety, Tolerability, and Fed/Fasted Pharmacokinetics of Repeated Oral Doses of SEN0014196 |
Completed |
NCT01485965 |
Phase 1 |
SEN0014196 |
31 |
(+)-Alpha-Dihydrotetrabenazine Phase I |
Completed |
NCT02844179 |
Phase 1 |
HTBZ |
32 |
An Exploratory Clinical Trial in Early Stage Huntington's Disease Patients to Assess Pharmacokinetics, Candidate Pharmacodynamic Measures of Target Engagement and Disease Modulation as Well as Acute Phenotypical Effects Following Multiple Oral Doses of SEN0014196. |
Completed |
NCT01485952 |
Phase 1 |
SEN0014196 (Low Dose);SEN0014196 (High Dose);Placebo |
33 |
The Effects of Music Therapy on Depression, Chorea and Other Symptoms of Huntington's Disease |
Completed |
NCT00178360 |
Phase 1 |
|
34 |
An Open Label, Phase Ib Study to Evaluate the Impact of Low Doses of Nilotinib Treatment on Safety, Tolerability and Biomarkers in Huntington's Disease |
Recruiting |
NCT03764215 |
Phase 1 |
Nilotinib 150 MG |
35 |
PINS Stimulator System for Deep Brain Stimulation in Huntington's Disease |
Unknown status |
NCT02263430 |
|
|
36 |
Exploring Hypertonia in Children With Cerebral Palsy- a Population-based Approach. |
Unknown status |
NCT01744158 |
|
|
37 |
Deep Brain Stimulation in the Treatment of Intractable Movement Disorders ( Parkinson's Disease, Essential Tremors and Dystonia) |
Unknown status |
NCT03562403 |
|
|
38 |
Finding Genes With NGS Techniques in Whom Mutations Cause Neurological Diseases |
Unknown status |
NCT02340871 |
|
|
39 |
Impact of Xenazine(Tetrabenazine)on Gait and Functional Activity in Individuals With Huntington's Disease |
Completed |
NCT01451463 |
|
|
40 |
Intravenous Immunoglobulins as Effective Treatment in Sydenham's Chorea |
Completed |
NCT00615797 |
|
standard interventions penicillin VK and haloperidol |
41 |
Characterization of Cardiac and Skeletal Myopathy, Risk Evaluation, and Phenotype-Genotype Correlation in Patients With Neuroacanthocytosis |
Completed |
NCT00007228 |
|
|
42 |
Plasma Adiponectin Levels and Relations With Cytokines in Children With Acute Rheumatic Fever |
Completed |
NCT01886846 |
|
|
43 |
Accelerated Diffusion MRI as a Potential Image Based Biomarker for Hungtington Disease |
Completed |
NCT01884181 |
|
|
44 |
Comparative 2-D Tumor Analysis in Familial Gliomas |
Completed |
NCT00125710 |
|
|
45 |
NIAID Clinical Center Genomics Opportunity Protocol |
Completed |
NCT02417766 |
|
|
46 |
Functional Neuro-Imaging of Strategy Use During Human Behavior |
Completed |
NCT00728741 |
|
|
47 |
Assessment The Effects of Proprioceptive Neuromuscular Facilitation, Myofascial Releasing Maneuvers and Home Exercises on Pain and Jaw Function in Patients With Bruxism |
Completed |
NCT03499665 |
|
|
48 |
I2PETPG - Quantification and Localisation of Imidazoline2 Binding Sites in a Group of Participants Diagnosed With Alzheimer's Disease Using 11C‑BU99008: a Positron Emission Tomography Study |
Completed |
NCT02874820 |
Early Phase 1 |
Idazoxan |
49 |
I2PETHV - Quantification and Localisation of Imidazoline2 Binding Sites in Healthy Volunteers Using [11C]BU99008 a Positron Emission Tomography Study |
Completed |
NCT02323217 |
Early Phase 1 |
Idazoxan;Isocarboxazid |
50 |
Wearable Sensors for Quantitative Assessment of Motor Impairment in Huntington's Disease |
Recruiting |
NCT03599076 |
|
|
Cochrane evidence based reviews: chorea
|